MAM
CLDX icon

Martingale Asset Management’s Celldex Therapeutics CLDX Stock Holding History

Martingale Asset Management’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-1,587
Closed -$86K – 945
2017
Q1 		$86K Hold
1,587
– – ﹤0.01% 927
2016
Q4 		$85K Sell
1,587
-103
-6% -$5.86K ﹤0.01% 952
2016
Q3 		$103K Sell
1,690
-1
-0.1% -$62 ﹤0.01% 939
2016
Q2 		$112K Hold
1,691
– – ﹤0.01% 824
2016
Q1 		$96K Sell
1,691
-40
-2% -$4.5K ﹤0.01% 792
2015
Q4 		$408K Buy
1,731
+60
+4% +$13.1K 0.01% 695
2015
Q3 		$265K Hold
1,671
– – 0.01% 763
2015
Q2 		$633K Buy
1,671
+96
+6% +$38.1K 0.01% 639
2015
Q1 		$659K Buy
+1,575
New +$563K 0.02% 643

Other funds holding CLDX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
KE
KLP Enterprises Branford, Connecticut $1.97M AUM
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Martingale Asset Management's CLDX Position: Q2 2017 in Review

Martingale Asset Management sold out of Celldex Therapeutics (CLDX) in Q2 2017, closing a stake of 1,587 shares — an estimated $86K sold.

Martingale Asset Management first reported a position in CLDX in Q1 2015 and held it in 9 quarters. The position peaked at $659K in Q1 2015. 130 funds tracked by Wall St. Rank hold CLDX as of Q2 2017.

  • Martingale Asset Management reported no remaining Celldex Therapeutics position as of Q2 2017 after selling out during the quarter.
  • Martingale Asset Management sold 1,587 Celldex Therapeutics shares in Q2 2017, an estimated $86K.
  • Martingale Asset Management first reported a position in Celldex Therapeutics in Q1 2015 and held it in 9 quarters.
  • Martingale Asset Management's Celldex Therapeutics position peaked at $659K in Q1 2015.
  • 130 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2017.

Based on Martingale Asset Management's 13F filing for Q2 2017, filed 10 Aug 2017.